Modified neck dissection for metastatic testicular carcinoma

Area of Science:

• Oncology
• Urology

Background:

• Testicular carcinoma is a unique malignancy with a favorable prognosis, even in advanced stages.
• Treatment involves chemotherapy, surgical resection of residual disease, and monitoring via serum tumor markers.

Observation:

• Serum markers, including human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP), are crucial for monitoring treatment response.
• Normalization of markers post-chemotherapy suggests disease elimination or conversion to teratoma.
• Persistent elevation of markers indicates residual or recurrent carcinoma, necessitating further chemotherapy.

Findings:

• Surgical resection of residual masses is recommended after marker normalization.
• The otolaryngologist is involved in diagnosing and resecting residual neck disease.
• Metastatic testicular carcinoma can manifest as a supraclavicular neck mass, requiring consideration in differential diagnoses.

Implications:

• Aggressive management combining chemotherapy and surgery leads to high cure rates for testicular carcinoma.
• Serum marker monitoring is essential for guiding treatment decisions and assessing prognosis.
• Early recognition and surgical management of metastatic disease, including neck masses, are critical for successful outcomes.